An Overview of a Study Combining Nivolumab With Ibrutinib in CLL and Richter Transformation
December 6th 2016Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase II trial combining nivolumab (Opdivo) with ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL) and richter transformation (RT) during the American Society of Hematology (ASH) Annual Meeting.<br />
Watch
An Overview of the PROGRESS II Trial in Acute Leukemia and Myelodysplastic Syndrome
December 4th 2016Miguel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, and director, Adult Bone Marrow Transplantation Fellowship Program, gives an overview of the PROGRESS II trial in acute leukemia and myelodysplastic syndrome during the ASH Annual Meeting.
Watch
Findings of the SIRFLOX Study in Metastatic Colorectal Cancer
November 30th 2016Navesh K. Sharma, DO, PhD, associate professor of Radiology, Division of Radiology and Oncology, Penn State Hershey Medical Center, section chief of Radiation Oncology, Penn State Health St. Joseph Cancer Center, discusses the results of the SIRFLOX study in patients with metastatic colorectal cancer (mCRC).
Watch
The Benefits of myPlan to Help Identify High-Risk Patients With NSCLC
November 24th 2016Jeffrey Schneider, MD, chief of hematology and medical oncology, Winthrop University Hospital, discusses the benefits of Myriad's myPlan in determining high-risk patients with non-small cell lung cancer (NSCLC).
Watch
Erlotinib Plus Bevacizumab in EGFR-Mutant NSCLC
November 18th 2016Howard L. “Jack” West, MD, thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the combination of erlotinib plus bevacizumab (Avastin) as a frontline treatment for patients with unresectable advanced, metastatic, or recurrent <em>EGFR</em>-mutant non-small cell lung cancer (NSCLC).
Watch